Top Markets
#1 Pleasing Gold Pleasing Gold +1,045.26%
#2 Islamic Coin Islamic Coin +154.26%
#3 PulseChain PulseChain +56.32%
#4 BOOK OF MEME BOOK OF MEME +44.02%
#5 DogBull DogBull +36.47%
#6 Ontology Gas Ontology Gas +24.72%
#7 Nockchain Nockchain +19.16%
#8 Neiro Neiro +18.85%
#9 Pump.fun Pump.fun +16.48%
#10 Unit Pump Unit Pump +16.48%
Coin of the day
Pleasing Gold Pleasing Gold
Settings
Language
ENGLISH
Currency
USD
Theme
Mabion S.A. Mabion S.A.

Mabion S.A.

MAB
Rank in Stocks #27025
Mabion S.A. is a Polish biopharmaceutical firm dedicated to pioneering the... Mabion S.A. is a Polish biopharmaceutical firm dedicated to pioneering the development of biological drugs, primarily leveraging monoclonal antibody technology. The company oversees the full spectrum from research and development to the manufacturing and commercialization of therapies designed to combat a wide range of diseases, including neoplastic (cancer), autoimmune, metabolic, and neurological disorders. Key products in its portfolio include MabionCD20 and MabionHER2. Established in 2007, Mabion S.A. maintains its headquarters in Konstantynów Lódzki, Poland.
Share Price
$2.22
Market Cap
$35.85M
Change (1 day)
3.14%
Change (1 year)
-15.06%
Country
PL
Trade Mabion S.A. (MAB)

Category

Healthcare
Revenue for Mabion S.A. (MAB)
Revenue in Aug 2026 TTM: 0
According to Mabion S.A. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Mabion S.A. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH